Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial

Blood Pressure

Volumn 5, Issue 6, 1996, Pages 354-359

  Schmitz, G ^a   Stumpe, K O ^b   Herrmann, W ^a   Weidinger, G ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Product Development   (Germany)

Author keywords

Atenolol; Bunazosin; Hypertension; Lipoproteins; Serum lipids

Indexed keywords

APOLIPOPROTEIN; ATENOLOL; BUNAZOSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISRADIPINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029831180     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059609078074     Document Type: Article

References (28)

1. H-1,4-diazepin-1-yl)-6,7-dimethoxy-quinazoline HCl. Xenobiotics 1982; 12: 549-59.
2. Shoji J. Comparison of pre- and postsynaptic α-adrenoceptor blocking effects of E-643 in the isolated vas deferens of the rat. Jpn J Pharmacol 1981; 31: 361-8.
3. Igarashi T, Nakajima Y, Ohtake S. Comparison of effects of α-blocking agents on blood pressure and heart rate in unanesthetized spontaneously hypertensive (SHR) and normotensive rats. Clin Exp Pharmacol Physiol 1976; 3: 89-92.
4. Igarashi T, Nakajima Y, Ohtake S. Antihypertensive effect of combined traetment with α- and β-adrenergic blockers in the spontaneously hypertensive rats. Jpn Circ J 1977; 41: 903-11.
5. Hoshi K, Fujino S. Effects of alpha blockers on blood pressure and on the Ca-contracture of cat aortic strips. Jpn J Pharmacol 1980; 30: 427-35.
6. Kawasaki T, Uezono K, Abe I, Nakamuta S, Ueno M, Kawazoe N, Omae T. Antihypertensive effect of E-643, a new alpha-adrenergic agent. Eur J Clin Pharmacol 1981; 20: 399-405.
7. Leren P, Helgeland A, Holme I, Fosso PO, Hjermann I, Lund-Larsen PG. Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet 1980; 2: 4.
8. Goto Y. Effects of α- and β-blocker antihypertensive therapy on blood lipids; a multicenter trial. Am J Med 1984; 76: 72.
9. Sasaki J, Koga S, Uzawa H, Arakawa K. Comparative effects of bunazosin and propranolol on serum lipids and apolipoproteins in patients with essentail hypertension. Int J Clin Pharmacol 1989; 27: 402-7.
10. 1-blocker, on plasma lipids in diabetic subjects with essential hypertension. Curr Ther Res 1989; 45: 677-83.
11. Holzgreve H, Distler A, Michaelis J, Philipp T, Wellek S. Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long-term double blind comparative trial. BMJ 1989; 229: 881-6.
12. Jamieson MJ, Webster J, Witte K, Huggins MM, MacDonald TM, et al. An evaluation of the A&D UA-751 semi-automated cuff-oscillometric sphygmomanometer. J Hypertens 1990; 8: 377-81.
13. Association for the Advancement of Medical Instrumentation. American national standard: electronic or automated sphygmomanometers. Arlington: Association for the Advancement of Medical Instrumentation, 1987.
14. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-53.
15. Langdon CD. Doxazosin: a study in a cohort of patients with hypertension in general practice - an interim report. Am Heart J 1991; 121: 268-72.
16. Cubeddu LX, Pool JL, Bloomfield R, Klotman, PE, Pickering, BI, Womboldt, DG, Nelson EB, Halperin A. Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension. Am J Hypertens 1988; 158-67.
17. Trost BN, Weismann P, Resien W, Claessens J, Streulens Y, Nelemanns F. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension. Am J Cardiol 1987; 59: 99G-104G.
18. Lehtonen A, Himanen P, Saraste M, Nittmyäki K, Marniemi J. Double bilind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins. Br J Clin Pharmacol 1986; 21: 77S-81S.
19. 1-adrenergic inhibitor for systemic hypertension. Am J Cardiol 1987; 59: 49G-50G.
20. Leren TP. Doxazosin increases low density lipoprotein receptor activity. Acta Pharmacol Toxicol 1985; 56: 269-72.
21. D'Eletto RD, Javitt NB. Effect of Doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol 1989; 12 Suppl 2: S1-S4.
22. Jansen H, Lammers R, Baggen MGA, Birkenhäger JC. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster. J Cardiovasc Pharmacol 1989; 12 Suppl 2, S5-S10.
23. 1-inhibition on lipid metabolism in the rat. J Cardiovasc Pharmacol 1987; 10 Suppl. 9, S27-S34.
24. Dall'Aglio E, Chang H, Reaven GM. Disparate effects of prazosin and propranolol on lipid metabolism in a rat model. Am J Med 1984; 76: 85.
25. Poulter N. Management of multiple risk factors for coronary heart disease in patients with hypertension. Am Heart J 1991; 121: 246-50.
26. Multiple Risk Factor Intervention Trial Research Group. Risk factor changes and mortality results. JAMA 1982; 248: 1465-77.
27. Levy D, Wilson PWF, Anderson KM, Castelli WP. Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study. Am Heart J 1990; 119: 712-7.
28. Wilson PWF, Castelli WP, Kannel WB. Coronary risk prediction in adults. The Framingham Heart Study. Am J Cardiol 1987; 59: 91G-94G.